Acute Charcot neuro-osteoarthropathy
- PMID: 26451965
- DOI: 10.1002/dmrr.2734
Acute Charcot neuro-osteoarthropathy
Abstract
Charcot neuro-osteoarthropathy (CN) is one of the most challenging foot complications in diabetes. Common predisposing and precipitating factors include neuropathy and increased mechanical forces, fracture and bone resorption, trauma and inflammation. In the last 15 years, considerable progress has been made in the early recognition of the acute Charcot foot when the X ray is still negative (stage 0 or incipient Charcot foot). Recent advances in imaging modalities have enabled the detection of initial signs of inflammation and underlying bone damage before overt bone and joint destruction has occurred. Casting therapy remains the mainstay of medical therapy of acute CN. If timely instituted, offloading can arrest disease activity and prevent foot deformity. In cases with severe deformity, modern surgical techniques can correct the unstable deformity for improved functional outcome and limb survival. Emerging new studies into the cellular mechanisms of severe bone destruction have furthered our understanding of the mechanisms of pathological bone and joint destruction in CN. It is hoped that these studies may provide a scientific basis for new interventions with biological agents.
Keywords: Charcot neuro-osteoarthropathy; casting therapy; diabetes; magnetic resonance imaging; osteoclastic activity; reconstructive surgery.
Copyright © 2016 John Wiley & Sons, Ltd.
Similar articles
-
Surgical treatment of the Charcot foot.Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:287-91. doi: 10.1002/dmrr.2750. Diabetes Metab Res Rev. 2016. PMID: 26813619 Review.
-
Surgical management of Charcot neuroarthropathy of the ankle and hindfoot in patients with diabetes.Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:292-6. doi: 10.1002/dmrr.2748. Diabetes Metab Res Rev. 2016. PMID: 26452590
-
The diabetic foot in 2015: an overview.Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:169-78. doi: 10.1002/dmrr.2740. Diabetes Metab Res Rev. 2016. PMID: 26451519 Review.
-
IWGDF guidance on footwear and offloading interventions to prevent and heal foot ulcers in patients with diabetes.Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:25-36. doi: 10.1002/dmrr.2697. Diabetes Metab Res Rev. 2016. PMID: 26813614 No abstract available.
-
Management of the diabetic Charcot foot.Diabetes Metab Res Rev. 2000 Sep-Oct;16 Suppl 1:S59-65. doi: 10.1002/1520-7560(200009/10)16:1+<::aid-dmrr134>3.0.co;2-n. Diabetes Metab Res Rev. 2000. PMID: 11054891
Cited by
-
Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study.Diabetes Care. 2021 Jul;44(7):1613-1621. doi: 10.2337/dc21-0008. Epub 2021 Jun 4. Diabetes Care. 2021. PMID: 34088701 Free PMC article. Clinical Trial.
-
Trends in the relation between hyperglycemia correction and active Charcot neuroarthropathy: results from the EPICHAR study.BMJ Open Diabetes Res Care. 2022 Sep;10(5):e002380. doi: 10.1136/bmjdrc-2021-002380. BMJ Open Diabetes Res Care. 2022. PMID: 36215101 Free PMC article.
-
The Role of Bone Scintigraphy with SPECT/CT in the Characterization and Early Diagnosis of Stage 0 Charcot Neuroarthropathy.J Clin Med. 2020 Dec 21;9(12):4123. doi: 10.3390/jcm9124123. J Clin Med. 2020. PMID: 33371286 Free PMC article.
-
Predictive Radiographic Values for Foot Ulceration in Persons with Charcot Foot Divided by Lateral or Medial Midfoot Deformity.J Clin Med. 2022 Jan 18;11(3):474. doi: 10.3390/jcm11030474. J Clin Med. 2022. PMID: 35159926 Free PMC article.
-
An overview of Charcot's neuroarthropathy.J Clin Transl Endocrinol. 2020 Oct 28;22:100239. doi: 10.1016/j.jcte.2020.100239. eCollection 2020 Dec. J Clin Transl Endocrinol. 2020. PMID: 33251117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical